Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

125 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
(18)F-FDG Is a Surrogate Marker of Therapy Response and Tumor Recovery after Drug Withdrawal during Treatment with a Dual PI3K/mTOR Inhibitor in a Preclinical Model of Cisplatin-Resistant Ovarian Cancer.
Lheureux S, Lecerf C, Briand M, Louis MH, Dutoit S, Jebahi A, Giffard F, Fournier CB, Batalla A, Poulain L, Aide N. Lheureux S, et al. Transl Oncol. 2013 Oct 1;6(5):586-95. doi: 10.1593/tlo.13100. eCollection 2013. Transl Oncol. 2013. PMID: 24151539 Free PMC article.
A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: a study of the Princess Margaret, Chicago and California Consortia.
Castonguay V, Lheureux S, Welch S, Mackay HJ, Hirte H, Fleming G, Morgan R, Wang L, Blattler C, Ivy PS, Oza AM. Castonguay V, et al. Among authors: lheureux s. Gynecol Oncol. 2014 Aug;134(2):274-80. doi: 10.1016/j.ygyno.2014.05.016. Epub 2014 May 29. Gynecol Oncol. 2014. PMID: 24882554 Clinical Trial.
Targeting the microenvironment in ovarian cancer.
Lheureux S, Oza AM. Lheureux S, et al. Lancet Oncol. 2015 May;16(5):485-6. doi: 10.1016/S1470-2045(15)70157-9. Epub 2015 Apr 14. Lancet Oncol. 2015. PMID: 25882985 No abstract available.
A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California Phase II Consortia.
Hirte H, Lheureux S, Fleming GF, Sugimoto A, Morgan R, Biagi J, Wang L, McGill S, Ivy SP, Oza AM. Hirte H, et al. Among authors: lheureux s. Gynecol Oncol. 2015 Jul;138(1):55-61. doi: 10.1016/j.ygyno.2015.04.009. Epub 2015 Apr 17. Gynecol Oncol. 2015. PMID: 25895616 Clinical Trial.
Safety evaluation of olaparib for treating ovarian cancer.
Lheureux S, Bowering V, Karakasis K, Oza AM. Lheureux S, et al. Expert Opin Drug Saf. 2015 Aug;14(8):1305-16. doi: 10.1517/14740338.2015.1045875. Epub 2015 Jun 8. Expert Opin Drug Saf. 2015. PMID: 26051946 Review.
Ovarian cancer treatment: The end of empiricism?
Lheureux S, Karakasis K, Kohn EC, Oza AM. Lheureux S, et al. Cancer. 2015 Sep 15;121(18):3203-11. doi: 10.1002/cncr.29481. Epub 2015 Jun 10. Cancer. 2015. PMID: 26096019 Free PMC article. Review.
125 results